Exploring New Frontiers in Addiction Treatment: Can GLP-1s support Opioid Use Disorder?

A groundbreaking new study funded by Center for Addition Science & Policy Research (CASPR) is exploring the potential of GLP-1 receptor analysts – commonly used for managing diabetes and obesity – to reduce opioid overdose rates and address opioid use disorder (OUD) among veterans. The research is happening in partnership with the Philadelphia Research and Education Foundation (PREF), a NAVREF Member. ?

?While GLP-1 medications like Wegovy & Ozempic have gained tremendous popularity over the last year for their role in managing weight, the team at the PHILADELPHIA VA MEDICAL CENTER (led by Dr. Dave Oslin), is looking a thee impact of these medications on veterans with a history of OUD.?

Dr. Oslin, a Core Investigator at the Center for Health Equity Research & Promotion, noted that “GLP-1 receptor agonists have received a tremendous amount of attention related to weight loss and diabetes control.? There is emerging data that these medications may support reductions in substance misuse. If the science supports the clinical indication, these medications may be a tremendous asset in curbing the morbidity and mortality from addiction.”

Preliminary findings suggest?that GLP-1 receptor agonists may inadvertently reduce cravings beyond food, including for substances like alcohol and opioids. This study aims to validate these observations in a veteran population, potentially leading to a significant reduction in opioid overdoses. A decrease as substantial as 40-50% in overdose rates could redefine treatment protocols and offer new hope for veterans battling addiction.

This study is not just a stand-alone effort but the potential beginning of several collaborations between CASPR and the VA.